Global Alzheimer’s Platform (GAP) Foundation Unites 58 of the World’s Leading Research Sites With Goal of Doubling Clinical Trial Participation in USA

More than Half of All National Clinical Trials in Alzheimer’s Take Place at GAP Networked Sites Kansas City Pilot Program Increased Volunteer Trial Participation by 292%

WASHINGTON, D.C. (November 1, 2017) – Alzheimer’s disease affects more than 5.4 million Americans and costs taxpayers at least $153 billion dollars per year in Medicare and Medicaid expenses alone. It is projected that 14 million people in the U.S. will be afflicted with Alzheimer’s disease by 2050. The Global Alzheimer’s Platform (GAP) Foundation is implementing a new model designed to accelerate clinical trials and increase participation in research. Results of GAP’s Kansas City initiative, the Memory Strings Kansas City Alliance, demonstrated a 292% growth in people contacting their local Alzheimer’s disease research center. The Kansas City Alliance initiative also cut trial enrollment time in half. GAP’s initiatives are targeted to reduce the clinical trial cycle times by up to two years, with the goal of speeding the delivery of lifesaving therapies to patients.

“The first person cured of Alzheimer’s will be someone who participated in a clinical trial. The nation desperately needs a therapy for Alzheimer’s. Significantly improving the clinical trials process is critical to implementing those therapies,” commented John Dwyer, President of the Global Alzheimer’s Platform Foundation. “We know that our methodology for expediting trials is working. We are attacking a major hurdle in bringing therapies to patients.”

To accomplish its mission, the GAP Foundation is:

  • Establishing a state?of?the?art, online recruitment process for trial participants, covering individuals ranging from preclinical and pre?symptomatic conditions to mild and moderate Alzheimer’s disease.
  • Expanding GAP?Net, an integrated platform of
    trial?ready, high?performing clinical trial sites,
    dedicated to shortening the duration of trials.
    The research network includes: Stanford
    University, University of California San Francisco,
    Compass Research, Raleigh Neurological
    Associates, University of Southern California, the Cleveland Clinic, Northwestern University, Emory University, Mayo Clinic, Washington University, Howard University and many more.

More than 5 million Americans suffer from Alzheimer’s disease and that number is expected to

  • Of the 58 GAP?Net sites, 47 academic and private sites have agreed to share a single Institutional Review Board (IRB) creating the largest Alzheimer’s disease research network under a single IRB in North America. This unprecedented achievement allows for speedier AD trial launches while simultaneously protecting the rights and safety of participants.
  • Establishing a customized recruitment process that connects potential trial participants to GAP? Net research centers. This includes extensive initiatives to increase community engagement, both live and online.
  • Increasing the participation of the African American and Latino communities in clinical trials by establishing relationships between GAP?Net sites and the healthcare professionals serving these populations.
  • Launching, a digital platform connecting GAP?Net researchers, research volunteers, caregivers, advocates and local communities. The platform’s goal is to facilitate the inclusion of more people into clinical trials.

Curing Alzheimer’s disease depends on clinical trials and recruiting trial participants remains a global challenge. 85% of trials are delayed due to enrollment issues and more than 30% of total trial time is spent just on recruiting. One of the Global Alzheimer’s Platform Foundation’s primary goals is to establish a recruitment infrastructure to ensure speedy enrollment of targeted individuals into trials.

Sponsors currently supporting GAP’s initiatives include Ray and Dagmar Dolby Family Fund, Bright Focus Foundation, Laura and John Arnold Foundation, Alzheimer’s Drug Discovery Foundation, Janssen, Lilly, Roche, Eisai, Biogen, Lundbeck, Takeda, Pfizer and others.

Read the full release here.

To top